Trading update - Media comment and speculation

Summary by AI BETAClose X

Aptamer Group plc has issued a trading update to address media comment and speculation, confirming that its current cash position provides a runway through to June 2027, consistent with previous statements. This update reassures investors regarding the company's financial stability and operational outlook.

Disclaimer*

Aptamer Group PLC
07 January 2026
 

 

7 January 2026

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Trading update - Media comment and speculation

 

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, provides an update regarding media comment and speculation following the trading update released by the Company earlier today.  The Company confirms that the Group's cash position provides a runway through to June 2027 in line with the previous statements (see RNS 14 October 2025, "Full year results for the twelve months ended 30 June 2025").

 

- Ends -

 

For further information, please contact: 

 

Aptamer Group plc  

Dr Arron Tolley, Chief Executive Officer

+44 (0) 1904 217 404  

SPARK Advisory Partners Limited - Nominated Adviser    

Andrew Emmott   

+44 (0) 20 3368 3550  

Turner Pope Investments (TPI) Limited - Broker    

Andrew Thacker / Guy McDougall 

+44 (0) 20 3657 0050  

Northstar Communications Limited - Investor Relations

Sarah Hollins 

+44 (0) 113 730 3896

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100